A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

NCT04147416 | Completed Phase 2

• 1 other identifier: HSK3486-205
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multi-center, open-label, randomized, propofol-controlled phase II clinical trial.A total of ICU patients undergoing mechanical ventilation are intended to be enrolled and randomly assigned to HSK3486 group and propofol group in a 2:1 ratio.

Conditions

Sedation

Outcome Measures

Primary Outcomes (1)

• Mean time to sedation

  Defined as the mean time during which the hourly RASS is in the range of +1- -2 during the study treatment

  at day 1

Secondary Outcomes (6)

• Study drug use

  at day 1

• Minimum maintenance dose

  at day 1

• Unit weight dose of remedial drug

  at day 1

• Unit weight dose of remifentanil

  at day 1

• Extubation time

  at day 1

Study Arms (2)

HSK3486

EXPERIMENTAL

HSK3486 for Sedation

Drug: HSK3486 0.1-0.2 /0.3 mg / kg group

Propofol

ACTIVE COMPARATOR

Propofol for Sedation

Drug: Propofol 0.5-1.0/1.5 mg/kg group

Interventions

HSK3486 0.1-0.2 /0.3 mg / kg group DRUG

Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.

HSK3486

Propofol 0.5-1.0/1.5 mg/kg group DRUG

Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.

Propofol

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who need tracheal intubation for mechanical ventilation and need 6-24 h of sedation after randomization, as anticipated;
• The target RASS score is between +1 and -2;
• ≤ age \< 80 years old; with no restriction on gender;
• kg/m2 ≤ BMI ≤ 30 kg/m2;
• The patients or their family members well understand the purpose and significance of the trial, voluntarily participate in this clinical trial, and sign the informed consent form.

You may not qualify if:

• Patients known to be allergic to eggs, soy products, opioids and their antidotes, and propofol; patients having contraindications to propofol, opioids and their antidotes;
• Patients having the following medical history or evidence at screening, which may increase sedation/anesthesia risk:
• Cardiovascular system: Class III and IV heart failure by New York Heart Association (NYHA), Adams-Stokes syndrome; acute coronary syndrome (ACS) within 6 months prior to screening; bradycardia requiring medications and/or heart rate ≤ 50 beats/min; serious arrhythmia history such as Degree II-III atrioventricular block (excluding patients with pacemakers); acute and chronic myocarditis; systolic pressure ≤ 90 mmHg even when large dose of vasoactive drug (such as norepinephrine ≥ 0.6 μg/kg/min) is used;
• Patients with mental disorders (such as schizophrenia, depression, etc.) and cognitive impairment; past abuse history of psychotropics and anesthetics, and long-term use of psychotropics;
• Patients with moderate to severe hepatic and renal dysfunctions (liver function: Child-Pugh Grade B and C, scale in Annex 9; renal function: glomerular filtration rate eGFR ≤ 60 mL/(min•1.73 m2) \[eGFR is calculated with the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 × serum creatinine (SCr)-1.154 × age-0.203 × 0.742 (female)\]; patients under dialysis;
• Epileptic seizures, convulsions; craniocerebral injury, intracranial hypertension, cerebral aneurysms; Glasgow Coma Score (GCS) ≤ 12 (scale in Annex 6); SOFA \> 9 (scale in Annex 7);
• Expected survival ≤ 72 h;
• Laboratory measures at screening period meet the following criteria:
• Neutrophil count ≤ 1.0 × 10\^9/L;
• Platelet count ≤ 50 × 10\^9/L;
• Hemoglobin ≤ 70 g/L;
• Pregnant or lactating females; fertile females or males reluctant to receive contraception through the study; any subject planning for pregnancy within 1 month after the study (including male subject);
• Participated in other drug clinical trials within 1 month prior to screening; Other reasons rendering a subject unsuitable for participation in this study as per the judgment of the investigator.

Sponsors & Collaborators

• Sichuan Haisco Pharmaceutical Group Co., Ltd: lead

Study Sites (1)

The First Affiliated Hospital of Sun Yat-sen University

Guanzhou, Guangdong, China

Location

Related Publications (2)

• Liu Y, Zuo L, Li X, Nie Y, Chen C, Liu N, Chen M, Wu J, Guan X. Early sedation using ciprofol for intensive care unit patients requiring mechanical ventilation: a pooled post-hoc analysis of data from phase 2 and phase 3 trials. Ann Intensive Care. 2024 Oct 26;14(1):164. doi: 10.1186/s13613-024-01390-3.

  PMID: 39455495 DERIVED

• Liu Y, Yu X, Zhu D, Zeng J, Lin Q, Zang B, Chen C, Liu N, Liu X, Gao W, Guan X. Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial. Chin Med J (Engl). 2022 May 5;135(9):1043-1051. doi: 10.1097/CM9.0000000000001912.

  PMID: 34924506 DERIVED

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 30, 2019
• First Posted: November 1, 2019
• Study Start: November 22, 2019
• Primary Completion: May 31, 2020
• Study Completion: July 3, 2020
• Last Updated: May 27, 2022

Record last verified: 2022-05

Locations

CN (1)